The SusHi Tech Tokyo Global Startup Program 2024, an annual startup event hosted by the Tokyo Metropolitan Government, will be held on May 16-17 this year.
CancerFree Biotech Ltd., the only Taiwanese company selected for the startup competition, not only ranked among the top 20 companies in the world, but also won two Special Prizes from the Tokyo City Government and Japan’s Shimizu CORPORATION, demonstrating Taiwan’s leading position in the global biotechnology field.
Pohan Chen, CEO of CancerFree Biotech (fourth from left), the selected team and Yuriko Koike, the current Governor of Tokyo (Mayor of Tokyo).
Cancer stand-in medical treatment The world sees Taiwanese biomedical medicine
Asia’s leading international innovation and technology event, SusHi Tech Tokyo Global Startup Program 2024 (Sustainable High Tech, referred to as SusHi Tech), hosted by the Tokyo Metropolitan Government, was recently held in a grand manner, attracting 400 start-ups and 40,000 visitors, and exhibitors from more than 40 cities around the world. and the SusHi Tech Challenge 2024.
At the end of last year, CancerFree Biotech, which won the New Venture Award, stood out in the global team preliminary selection and became the only Taiwanese startup to enter the top 20, and went to Japan on May 15 to participate in the final selection, and successfully won two Special Prizes from the Tokyo City Government and Shimizu Construction Co., Ltd. respectively.
It is understood that Shimizu Construction Co., Ltd. has invested in the construction of hospitals in the past, and this competition provides the winner of the special prize with the right to use office space for up to one year and other incentives.
“Put the Patient First was the company’s top motto when it was founded, and the team is now working on developing personalized anti-cancer drug testing technology to reduce the risk of cancer treatment and find new treatment opportunities for cancer patients,” said Pohan Chen, CEO of CancerFree Biotech. This technology, known as “stand-in medicine”, uses a proprietary culture technology to create a personalized tumor model for the patient, so as to “replace” the patient for drug response testing. It is hoped that through this international stage exhibition, the development of global precision cancer treatment will be further promoted. The success of this award is not only an affirmation of the company’s technology and team, but also an international recognition of Taiwan’s innovative strength.
The event attracted a large number of distinguished guests, including Tokyo Governor Yuriko Koike, Harvard Business Review Editor-in-Chief Adi Ignatius, and representatives from Bloomberg Associates, The Edgeof/Mistletoe, and Suntory Corporation. In addition, Jen Carter, Global Chief Technology Officer of Google.org, and John Roos, Founding Partner of Geodesic Capital and former U.S. Ambassador to Japan, were also in attendance to discuss the issues affecting the world and establish Tokyo as an incubator for solving global urban challenges.
Business Media Report News Link: https://sunmedia.tw/news/Industry-information/CancerFree-20240517
